Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
Condition: Obesity; Drug Interventions: Drug: metformin+sibutramine; Drug: sibutramine+ microcrystalline cellulose Sponsor: Promomed, LLC Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
Condition: Obesity Interventions: Drug: metformin+sibutramine; Drug: sibutramine+ microcrystalline cellulose Sponsor: Promomed, LLC Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
Condition: Obesity; Drug Interventions: Drug: metformin+sibutramine; Drug: sibutramine+ microcrystalline cellulose Sponsor: Promomed, LLC Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
Condition: Obesity Interventions: Drug: metformin+sibutramine; Drug: sibutramine+ microcrystalline cellulose Sponsor: Promomed, LLC Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
Condition: Obesity; Drug Interventions: Drug: metformin+sibutramine; Drug: sibutramine+ microcrystalline cellulose Sponsor: Promomed, LLC Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2023 Category: Research Source Type: clinical trials
Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/Topiramate in Overweight Comorbidities/Obesity
Conditions: Overweight; Obesity Intervention: Other: Source document data collection Sponsor: Eurofarma Laboratorios S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2022 Category: Research Source Type: clinical trials
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
Conditions: Overweight; Obesity Interventions: Drug: ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg; Drug: ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg; Drug: SIB Group Sibus (Sibutramine) 15mg; Drug: Placebo Group Sponsor: Eurofarma Laboratorios S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2022 Category: Research Source Type: clinical trials
Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/Topiramate in Overweight Comorbidities/Obesity
Conditions: Overweight; Obesity Intervention: Other: Source document data collection Sponsor: Eurofarma Laboratorios S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2022 Category: Research Source Type: clinical trials
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
Conditions: Overweight; Obesity Interventions: Drug: ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg; Drug: ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg; Drug: SIB Group Sibus (Sibutramine) 15mg; Drug: Placebo Group Sponsor: Eurofarma Laboratorios S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2022 Category: Research Source Type: clinical trials
Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/Topiramate in Overweight Comorbidities/Obesity
Conditions: Overweight; Obesity Intervention: Other: Source document data collection Sponsor: Eurofarma Laboratorios S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2022 Category: Research Source Type: clinical trials
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
Conditions: Overweight; Obesity Interventions: Drug: ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg; Drug: ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg; Drug: SIB Group Sibus (Sibutramine) 15mg; Drug: Placebo Group Sponsor: Eurofarma Laboratorios S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2022 Category: Research Source Type: clinical trials
